Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| NCT ID | NCT03596281 |
| Title | Pembrolizumab in Combination With Bevacizumab and Pegylated Liposomal Doxorubicin in Patients With Ovarian Cancer (PEMBOV) |
| Acronym | PEMBOV |
| Recruitment | Completed |
| Gender | female |
| Phase | Phase I |
| Variant Requirements | No |
| Sponsors | Gustave Roussy, Cancer Campus, Grand Paris |
| Indications | |
| Therapies | |
| Age Groups: | adult | senior |
| Covered Countries | FRA |